Price range: $51.69 through $294.99
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist studied for MC3R/MC4R signaling in hypothalamic and rodent behavior research.
PT-141, known by its generic name bremelanotide, is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was derived from Melanotan II and differs from it by having a free carboxylic acid at the C-terminus instead of an amide. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. A lactam bridge between aspartic acid and lysine constrains the backbone, which increases resistance to proteolysis compared with linear melanocortin peptides.
Melanocortin receptors are a family of five G protein-coupled receptors, MC1R through MC5R. Bremelanotide acts mainly at MC3R and MC4R, which are expressed in the hypothalamus and other brain regions. MC4R in particular sits in central pathways that regulate energy balance and motivated behavior. Where Melanotan II was studied first for skin pigmentation, PT-141 was developed with its central nervous system activity in view.
Rodent research, much of it from Palatin Technologies and academic collaborators, has examined its effects in sexual behavior models, including solicitation behavior in female rats, and on dopamine release in the medial preoptic area. The peptide is also used as a pharmacological tool for studying MC4R signaling separately from α-MSH. For an MC1R-selective comparison, see Melanotan I.
For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic. Sold to qualified researchers for in-vitro and laboratory research.
| Weight | 10mg, 50mg, 100mg |
|---|
